Norstella has launched NorstellaLinQ, a fully integrated data asset designed to streamline drug development and commercialization for the biopharmaceutical industry. The platform combines real-world data (RWD) with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage, and commercial intelligence data, aiming to provide comprehensive insights across the entire product lifecycle.
Addressing Data Integration Challenges
According to a recent Norstella survey, nearly half of pharma executives consider data integration and cleanliness as major obstacles to adopting new technologies. NorstellaLinQ addresses these challenges by providing integrated data and insights, helping clients refine their drug development strategies and accelerate decision-making.
"NorstellaLinQ isn’t just about bringing together data," said Mike Gallup, CEO of Norstella. "It’s about creating the only solution in the market that links real-world patient data with the proprietary intelligence of Norstella’s most trusted brands that have powered the pharmaceutical industry for decades."
Comprehensive Data Integration and Predictive Power
NorstellaLinQ integrates over 74 billion data points, including insights from 500,000 investigators, clinical trials across 185 countries, and thousands of forecasts. This extensive dataset supports portfolio planning and optimizes protocol design and investigator selection. The platform also uses AI, large language models (LLMs), and machine learning on a cloud infrastructure to analyze structured and unstructured data.
The system has tagged 1.5 million records to 55 custom and standard ontologies, covering aspects from indication and dosage route to mechanism of action and drug target. This allows for the synthesis of vast datasets, providing faster and more actionable insights.
Applications Across the Biopharma Ecosystem
NorstellaLinQ supports various teams within biopharmaceutical companies:
- Clinical operations teams can optimize protocol design and investigator selection.
- Clinical trial teams can identify and recruit medically complex patients.
- Brand teams can use predictive analytics to anticipate patient behavior.
- Pharma teams can analyze physician notes to understand clinical decision-making.
- Health Economics and Outcomes Research (HEOR) teams can generate evidence for improved patient outcomes and cost-benefit analysis.
- Commercial teams can target patients based on clinical criteria.
- Market access teams can track time to treatment and advocate for better access to therapies.
